PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells

Oncogene

Volumn 33, Issue 49, 2014, Pages 5601-5608

  Yoshida, H ^a   Miyachi, M ^a   Sakamoto, K ^a   Ouchi, K ^a   Yagyu, S ^a   Kikuchi, K ^a   Kuwahara, Y ^a   Tsuchiya, K ^a   Imamura, T ^a   Iehara, T ^a   Kakazu, N ^b   Hojo, H ^c   Hosoi, H ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

inhibiting differentiation; PAX3 FOXO1A; PAX3 NCOA2; rhabdomyosarcoma; tumorigenesis

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; NCOA2 PROTEIN, HUMAN; NCOA2 PROTEIN, MOUSE; NUCLEAR RECEPTOR COACTIVATOR 2; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN; PAX3 PROTEIN, MOUSE;

ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CELL MOTION; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FUSION; GENE TRANSLOCATION; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; MUSCLE DEVELOPMENT; MUTATION; NUDE MOUSE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TRANSCRIPTION INITIATION; WOUND HEALING;

ANIMALS; BINDING SITES; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MUSCLE DEVELOPMENT; MUTATION; NUCLEAR RECEPTOR COACTIVATOR 2; ONCOGENE FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TRANSCRIPTIONAL ACTIVATION; TRANSLOCATION, GENETIC; WOUND HEALING;

EID: 84887060798     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.491     Document Type: Article

References (41)

1. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher 3rd FJ, Emanuel BS et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5: 230-235.
2. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2002; 20: 2672-2679.
3. Tremblay P, Gruss P. Pax: genes for mice and men. Pharmacol Ther 1994; 61: 205-226.
4. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 6: 52-62.
5. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J 1991; 10: 1135-1147.
6. Jostes B, Walther C, Gruss P. The murine paired box gene, Pax7, is expressed specifically during the development of the nervous and muscular system. Mech Dev 1990; 33: 27-37.
7. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001; 20: 5736-5746.
8. Anderson J, Ramsay A, Gould S, Pritchard-Jones K. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 2001; 159: 1089-1096.
9. Lam PY, Sublett JE, Hollenbach AD, Roussel MF. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA-binding domain. Mol Cell Biol 1999; 19: 594-601.
10. Bernasconi M, Remppis A, Fredericks WJ, Rauscher 3rd FJ, Schafer BW. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 1996; 93: 13164-13169.
11. Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen CL, Sung YS et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 2013; 52: 538-550.
12. Sumegi J, Streblow R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 2010; 49: 224-236.
13. Hosoi H, Kakazu N, Konishi E, Tsuchihashi Y, Hada S, Amaya E et al. A novel PAX3 rearrangement in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet 2009; 189: 98-104.
14. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP-1 a novel mouse protein that serves as transcriptional coactivator in yeast for the hormone binding domains of steroid receprtors. Proc Natl Acad Sci USA 1996; 93: 4946-4952.
15. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand dependent activation function AF-2 of nuclear receptors. EMBO J 1996; 15: 3667-3675.
16. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP bindingdependent and -independent pathways. EMBO J 1998; 17: 507-519.
17. Chen SL, Dowhan DH, Hosking BM, Muscat GE. The steroid receptor coactivator, GRIP-1, is necessary for MEF-2C-dependent gene expression and skeletal muscle differentiation. Genes Dev 2000; 14: 1209-1228
18. Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ et al. Nuclear receptorbinding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 1998; 12: 302-313.
19. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol 1998; 12: 1172-1183.
20. Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ et al. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol 1999; 19: 6164-6173.
21. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT et al. Regulation of transcription by a protein methyltransferase. Science 1999; 284: 2174-2177.
22. Chen D, Huang SM, Stallcup MR. Synergistic, p160 coactivatordependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem 2000; 275: 40810-40816.
23. Teyssier C, Chen D, Stallcup MR. Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function. J Biol Chem 2002; 277: 46066-46072.
24. Lee YH, Coonrod SA, Kraus WL, Jelinek MA, Stallcup MR. Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination. Proc Natl Acad Sci USA 2005; 102: 3611-3616.
25. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997; 387: 733-736.
26. McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 1998; 21: 3357-3368.
27. Nakae J, Cao Y, Daitoku H, Fukamizu A, Ogawa W, Yano Y et al. The LXXLL motif of murine forkhead transcription factor FoxO1 mediates Sirt1-dependent transcriptional activity. J Clin Invest 2006; 116: 2473-2483.
28. Deguchi K, Ayton PM, Carapeti M, Kutok JL, Snyder CS, Williams IR et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 2003; 3: 259-271.
29. Calhabeu F, Hayashi S, Morgan JE, Relaix F, Zammit PS. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Oncogene 2013; 32: 651-662.
30. Jothi M, Nishijo K, Keller C, AKT Mal AK. and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. Cell Cycle 2012; 11: 895-908.
31. Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008; 365: 568-574.
32. Finckenstein FG, Shahbazian V, Davicioni E, Ren YX, Anderson MJ. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene 2008; 27: 2004-2014.
33. Zhang Y, Schwartz J, Wang C. Comparative analysis of paired- and homeodomainspecific roles in PAX3-FKHR oncogenesis. J Clin Exp Pathol 2009; 2: 370-383.
34. Wang W, Kumar P, Wang W, Epstein J, Helman L, Moore JV et al. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 1998; 58: 4426-4433.
35. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008; 68: 9583-9588.
36. Parker D, Rivera M, Zor T, Henion-Caude A, Radhakrishnan I, Kumar A et al. Role of secondary structure in discrimination between constitutive and inducible activators. Mol Cell Biol 1999; 19: 5601-5607.
37. Litterst CM, Pfitzner E. An LxxLL motif in thetransactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1. J Biol Chem 2002; 277: 36052-36060.
38. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997; 387: 677-684.
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DD C(T)) method. Methods 2001; 25: 402-408.
40. Hamburger AW, Salmon SE, Kim MB, Trent JM, Soehnlen BJ, Alberts DS et al. Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 1978; 38: 4118-4130.
41. Tsuchiya K, Hosoi H, Misawa-Furihata A, Houghton PJ, Sugimoto T. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells. Int J Oncol 2007; 31: 41-47.